Differing Severities of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (IPF): Insights From the INPULSIS® Trials

Respiratory Research - United Kingdom
doi 10.1186/s12931-019-1037-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Idiopathic Pulmonary Fibrosis Acute Exacerbations: Where Are We Now?

Expert Review of Respiratory Medicine
ImmunologyPublic HealthAllergyEnvironmentalPulmonaryRespiratory MedicineOccupational Health
2014English

Procalcitonin-Guided Antibiotic Use in Acute Exacerbations of Idiopathic Pulmonary Fibrosis

International Journal of Medical Sciences
Medicine
2013English

Predictors of Death or Lung Transplant After a Diagnosis of Idiopathic Pulmonary Fibrosis: Insights From the IPF-PRO Registry

Respiratory Research
PulmonaryRespiratory Medicine
2019English

Prs27 - Economic Burden of Idiopathic Pulmonary Fibrosis (Ipf) in China

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Idiopathic Pulmonary Fibrosis in Sweden: Report From the First Year of Activity of the Swedish IPF-Registry

European Clinical Respiratory Journal
2016English

Idiopathic Pulmonary Fibrosis (IPF) ― Common Practice in Poland Before the “Antifibrotic Drugs Era”

Advances in Respiratory Medicine
PulmonaryRespiratory Medicine
2017English

Idiopathic Pulmonary Fibrosis: Lessons From Clinical Trials Over the Past 25 Years

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2017English

Acute Exacerbation of Idiopathic Pulmonary Fibrosis: Shifting the Paradigm

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2015English

Idiopathic Pulmonary Fibrosis

Pulmonologiya
PulmonaryRespiratory Medicine
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy